COLL - コレギウム・ファ―マシュ―ティカル （Collegium Pharmaceutical Inc.）COLLのニュース
Collegium Pharmaceutical, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:COLL) 2023/02/24 03:07:36 Seeking Alpha
The following slide deck was published by Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call Transcript 2023/02/24 03:07:01 Seeking Alpha
Collegium Pharmaceutical, Inc. (NASDAQ:NASDAQ:COLL) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsChristopher James - Vice President of Investor Relations…
Collegium Pharmaceutical Non-GAAP EPS of $1.09 misses by $0.17, revenue of $129.62M beats by $4.41M 2023/02/23 21:45:04 Seeking Alpha
Collegium Pharmaceutical press release (COLL): Q4 Non-GAAP EPS of $1.09 misses by $0.17.Revenue of $129.62M (+373.8% Y/Y) beats by $4.41M.
Collegium Pharmaceutical: Q4 Earnings Snapshot 2023/02/23 21:21:18 WTOP
STOUGHTON, Mass. (AP) — STOUGHTON, Mass. (AP) — Collegium Pharmaceutical Inc. (COLL) on Thursday reported a loss of $7.2 million…
Earnings Outlook For Collegium Pharmaceutical 2023/02/22 16:00:59 Benzinga
Collegium Pharmaceutical (NASDAQ: COLL ) is set to give its latest quarterly earnings report on Thursday, 2023-02-23. Here''s what investors need to know before the announcement. Analysts estimate that Collegium Pharmaceutical will report an earnings per share (EPS) of $-0.14. Collegium Pharmaceutical bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Collegium Pharmaceutical, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:COLL) 2022/05/16 17:37:57 Seeking Alpha
The following slide deck was published by Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript 2022/05/11 02:45:07 Seeking Alpha
Collegium Pharmaceutical, Inc. (NASDAQ:NASDAQ:COLL) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications…
Collegium Pharmaceutical GAAP EPS of -$0.39, revenue of $83.75M 2022/05/10 20:29:08 Seeking Alpha
Collegium Pharmaceutical press release (COLL): Q1 GAAP EPS of -$0.39.Revenue of $83.75M (-4.5% Y/Y).2022 Guidance: Total product revenues are expected in the range of $450.0 million…
Collegium Pharmaceutical Q1 2022 Earnings Preview 2022/05/09 21:35:48 Seeking Alpha
Collegium Pharmaceutical (COLL) is scheduled to announce Q1 earnings results on Tuesday, May 10, after market close.The consensus EPS estimate is $0.90 and the consensus revenue estimate…
Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results 2022/04/26 20:00:00 GlobeNewswire
STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET. The Company will discuss its first quarter 2022 financial results and provide a corporate update.
Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference 2021/09/13 12:00:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its product portfolio were presented at the Annual PAINWeek National Conference, which took place September 7-11, 2021 in Las Vegas, NV.
Collegium to Participate in Upcoming Investor Conferences 2021/09/01 20:01:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences during the month of September:
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2021 Results - Earnings Call Transcript 2021/08/07 19:27:06 Seeking Alpha